Simulations Plus, Inc. (SLP)
$
16.96
-0.61 (-3.60%)
Key metrics
Financial statements
Free cash flow per share
0.4931
Market cap
341.1 Million
Price to sales ratio
4.3415
Debt to equity
0.0042
Current ratio
4.3681
Income quality
1.6175
Average inventory
0
ROE
0.0391
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Simulations Plus, Inc. develops drug discovery and development software that leverages artificial intelligence and machine learning technologies for modeling, simulation, and prediction of molecular properties globally. The company reported an earnings per share (EPS) of $0.50 indicating its profitability on a per-share basis. The income before tax ratio stands at 0.18 reflecting the pre-tax margin, while the cost of revenue amounts to $26,862,000.00 showcasing its production and operational expenses. The company's EBITDA is reported at $11,796,000.00 serving as a key indicator of operational profitability. Additionally, the gross profit ratio is 0.62 highlighting the efficiency of the company's production and sales operations. Operating through segments such as Simulations Plus, Cognigen, DILIsym, and Lixoft, the company provides products like GastroPlus, which simulates drug interactions in humans and animals, along with various simulation tools like DDDPlus and MembranePlus. Moreover, it offers advanced mechanistic and mathematical models through products like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Simulations Plus also features an Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor, and MedChem Designer, supplemented by MonolixSuite and PKPlus modeling products. Alongside, it offers consulting and contract research services that support pharmacometrics studies and regulatory submissions. Currently, the stock is affordable at $17.57 making it suitable for budget-conscious investors. It has a low average trading volume of 424,245.00 indicating lower market activity. With a market capitalization of $341,082,560.00 the company is classified as a small-cap player. Simulations Plus is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field. As the company continues to make strides in drug development technologies, it presents opportunities for investors looking to engage in a forward-thinking and strategically positioned entity in the life sciences domain.
Is Simulations Plus, Inc. (SLP) a good investment?
Investing in Simulations Plus, Inc. (SLP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Simulations Plus, Inc. (SLP)'s stock forecast?
Analysts predict Simulations Plus, Inc. stock to fluctuate between $16.72 (low) and $44.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Simulations Plus, Inc.'s market capitalization?
As of 2025-07-11, Simulations Plus, Inc.'s market cap is $341,082,560, based on 20,111,000 outstanding shares.
How does Simulations Plus, Inc. compare to competitors like Nvidia Corp?
Compared to Nvidia Corp, Simulations Plus, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Simulations Plus, Inc. pay dividends?
Simulations Plus, Inc. pays dividends. The current dividend yield is 0.60%, with a payout of $0.06 per share.
How can I buy Simulations Plus, Inc. (SLP) stock?
To buy Simulations Plus, Inc. (SLP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SLP. Place an order (Market, Limit, etc.).
What is the best time to invest in Simulations Plus, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Simulations Plus, Inc. stock ever split?
Simulations Plus, Inc.'s last stock split was 2:1 on 2007-10-02.
How did Simulations Plus, Inc. perform in the last earnings report?
Revenue: $70,013,000 | EPS: $0.50 | Growth: 0%.
Where can I find Simulations Plus, Inc.'s investor relations reports?
Visit https://www.simulations-plus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Simulations Plus, Inc.?
You can explore historical data from here
What is the all-time high and low for Simulations Plus, Inc. stock?
All-time high: $90.92 (2021-02-08) | All-time low: $16.72 (2025-06-25).
What are the key trends affecting Simulations Plus, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has rescheduled the release of its financial results and conference call for the third fiscal quarter ended May 31, 2025, which had previously been scheduled for July 2, 2025. The Compa.
seekingalpha.com
Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and the company's margins are under pressure. This situation is likely to persist, while the demand environment is soft. Simulations Plus' revenue multiple remains high, given its dependence on services and reliance on M&A to drive growth. As a result, further downside appears likely.
benzinga.com
Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.
zacks.com
Simulations Plus lowers FY25 revenue forecast and restructures operations as biotech headwinds hit services demand.
businesswire.com
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 mil.
zacks.com
Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.
businesswire.com
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. “Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are.
seekingalpha.com
Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation.
seekingalpha.com
Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and promising pipeline expansions, operational inefficiencies and rising costs raise concerns about near-term profitability. Management's ability to convert backlog into profitable revenue and stabilize margins is crucial for long-term shareholder value.
See all news
